Sensitivity can be restored by restraining CK2, and the authors suggest that combinatorial therapies based on CK2 targeting might potentially counteract therapeutic resistance in glioblastoma patients with aberrancies in p53, PTEN and CK2 [41]. The gene discussed is PTEN; the disease is glioblastoma.